Refractory Non-Hodgkin's Lymphoma
Refractory Non-Hodgkin's Lymphoma is a type of cancer that occurs in the lymphatic system and does not respond to standard treatments. It can be challenging to treat and may require alternative therapies.
Non-Hodgkin Lymphoma: IPH6501 Treatment Study
We are investigating a new drug, IPH6501, for patients with relapsed or refractory Non-Hodgkin Lymphoma. The study focuses on its safety and early signs of effectiveness in treating this type of cancer.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have a type of B-cell non-Hodgkin's lymphoma (like Diffuse Large B Cell Lymphoma or Follicular Lymphoma)?
- Have you received at least 2 prior treatments for your cancer, including an anti-CD20 antibody like rituximab?
- Have you had any major surgery in the last 4 weeks?
- Do you have a history of HIV or hepatitis B or C?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Iph6501
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Institut Bergonie
Hematology
Bordeaux, France
Centre Hospitalier Universitaire De Lille
Hematology
Loos, France
Institut Des Neurosciences De La Timone
CEPCM
Marseille, France
Sponsor: Innate Pharma
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.